These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

991 related articles for article (PubMed ID: 20597000)

  • 1. Clostridium difficile and the disease it causes.
    Norén T
    Methods Mol Biol; 2010; 646():9-35. PubMed ID: 20597000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clostridium-difficile-associated infections].
    Eckert C; Barbut F
    Med Sci (Paris); 2010 Feb; 26(2):153-8. PubMed ID: 20188046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergence of Clostridium difficile-associated disease in North America and Europe.
    Kuijper EJ; Coignard B; Tüll P; ; ;
    Clin Microbiol Infect; 2006 Oct; 12 Suppl 6():2-18. PubMed ID: 16965399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Epidemiological study of Clostridium difficile strains isolated in Jean-Verdier-René-Muret hospitals from 2001 to 2007].
    Poilane I; Fantinato C; Cruaud P; Collignon A
    Pathol Biol (Paris); 2008; 56(7-8):412-6. PubMed ID: 18842360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clostridium difficile infection in older adults: a review and update on its management.
    Kee VR
    Am J Geriatr Pharmacother; 2012 Feb; 10(1):14-24. PubMed ID: 22260856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain.
    O'Connor JR; Johnson S; Gerding DN
    Gastroenterology; 2009 May; 136(6):1913-24. PubMed ID: 19457419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection.
    Citron DM; Babakhani F; Goldstein EJ; Nagaro K; Sambol S; Sears P; Shue YK; Gerding DN
    Anaerobe; 2009 Dec; 15(6):234-6. PubMed ID: 19755166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clostridium difficile infection.
    Gröschel DH
    Crit Rev Clin Lab Sci; 1996; 33(3):203-45. PubMed ID: 8828001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular characterization, toxin detection and resistance testing of human clinical Clostridium difficile isolates from Lebanon.
    Berger FK; Rasheed SS; Araj GF; Mahfouz R; Rimmani HH; Karaoui WR; Sharara AI; Dbaibo G; Becker SL; von Müller L; Bischoff M; Matar GM; Gärtner B
    Int J Med Microbiol; 2018 Apr; 308(3):358-363. PubMed ID: 29478838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of cross-infection associated to a Brazilian PCR-ribotype of Clostridium difficile in a university hospital in Rio de Janeiro, Brazil.
    Balassiano IT; dos Santos-Filho J; Vital-Brazil JM; Nouér SA; Souza CR; Brazier JS; Ferreira Ede O; Domingues RM
    Antonie Van Leeuwenhoek; 2011 Feb; 99(2):249-55. PubMed ID: 20623188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vancomycin for the treatment of Clostridium difficile Infection: for whom is this expensive bullet really magic?
    Pepin J
    Clin Infect Dis; 2008 May; 46(10):1493-8. PubMed ID: 18419481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications.
    Debast SB; Bauer MP; Sanders IM; Wilcox MH; Kuijper EJ;
    J Antimicrob Chemother; 2013 Jun; 68(6):1305-11. PubMed ID: 23420839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Typing and subtyping of Clostridium difficile isolates by using multiple-locus variable-number tandem-repeat analysis.
    van den Berg RJ; Schaap I; Templeton KE; Klaassen CH; Kuijper EJ
    J Clin Microbiol; 2007 Mar; 45(3):1024-8. PubMed ID: 17166961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Investigation of toxin genes of Clostridium difficile strains isolated from hospitalized patients with diarrhoea at Marmara University Hospital].
    Deniz U; Ulger N; Aksu B; Karavuş M; Söyletir G
    Mikrobiyol Bul; 2011 Jan; 45(1):1-10. PubMed ID: 21341153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New trends in Clostridium difficile virulence and pathogenesis.
    Denève C; Janoir C; Poilane I; Fantinato C; Collignon A
    Int J Antimicrob Agents; 2009 Mar; 33 Suppl 1():S24-8. PubMed ID: 19303565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options.
    Lo Vecchio A; Zacur GM
    Curr Opin Gastroenterol; 2012 Jan; 28(1):1-9. PubMed ID: 22134217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of association of outcomes with treatment duration and microbiologic susceptibility data in Clostridium difficile infections in a non-NAP1/BI/027 setting.
    Venugopal AA; Riederer K; Patel SM; Szpunar S; Jahamy H; Valenti S; Shemes SP; Khatib R; Johnson LB
    Scand J Infect Dis; 2012 Apr; 44(4):243-9. PubMed ID: 22077148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe.
    Warny M; Pepin J; Fang A; Killgore G; Thompson A; Brazier J; Frost E; McDonald LC
    Lancet; 2005 Sep 24-30; 366(9491):1079-84. PubMed ID: 16182895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Recommendations for diagnosis and therapy of colitis caused by Clostridium difficile].
    Beneš J; Husa P; Nyč O
    Klin Mikrobiol Infekc Lek; 2012 Oct; 18(5):160-7. PubMed ID: 23208871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence and control of fluoroquinolone-resistant, toxin A-negative, toxin B-positive Clostridium difficile.
    Drudy D; Harnedy N; Fanning S; Hannan M; Kyne L
    Infect Control Hosp Epidemiol; 2007 Aug; 28(8):932-40. PubMed ID: 17620240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.